Literature DB >> 11962725

Anti-CD23 monoclonal antibody inhibits germline Cepsilon transcription in B cells.

Shingo Yabuuchi1, Takehiko Nakamura, William S Kloetzer, Mitchell E Reff.   

Abstract

A chimeric macaque/human (PRIMATIZED) anti-CD23 antibody, p6G5G1, demonstrated a strong inhibitory effect on IL-4 and anti-CD40 antibody-stimulated IgE production by human peripheral blood mononuclear cells (PBMCs). RNA analysis by both reverse transcription-polymerase chain reaction (RT-PCR) and Northern blot showed that p6G5G1 inhibited germline Cepsilon RNA synthesis, but had no effect on CD23 mRNA levels. These data suggest that p6G5G1 may inhibit immunoglobulin class switching to IgE through the inhibition of germline Cepsilon RNA synthesis. Early addition of p6G5G1 after stimulation by IL-4 and anti-CD40 was critical for IgE inhibition. In contrast, later addition of p6G5G1 still showed inhibition of increased levels of surface CD23, which is normally upregulated by stimulation with IL-4 and anti-CD40.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11962725     DOI: 10.1016/s1567-5769(01)00187-4

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

1.  The role of CD23 in IgE dependent signaling: implications from pharmacogenetics.

Authors:  Lanny J Rosenwasser; Jianfeng Meng; Marcia A Chan; Nicole M Gigliotti; Brianna E May
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

2.  Adrenergic regulation of IgE involves modulation of CD23 and ADAM10 expression on exosomes.

Authors:  Caroline J Padro; Todd M Shawler; Matthew G Gormley; Virginia M Sanders
Journal:  J Immunol       Date:  2013-10-18       Impact factor: 5.422

3.  CD23: an overlooked regulator of allergic disease.

Authors:  Daniel H Conrad; Jill W Ford; Jamie L Sturgill; David R Gibb
Journal:  Curr Allergy Asthma Rep       Date:  2007-09       Impact factor: 4.806

4.  IgE binds asymmetrically to its B cell receptor CD23.

Authors:  Balvinder Dhaliwal; Marie O Y Pang; Anthony H Keeble; Louisa K James; Hannah J Gould; James M McDonnell; Brian J Sutton; Andrew J Beavil
Journal:  Sci Rep       Date:  2017-03-31       Impact factor: 4.379

5.  The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.

Authors:  Pascal Gasser; Svetlana S Tarchevskaya; Pascal Guntern; Daniel Brigger; Rahel Ruppli; Noemi Zbären; Silke Kleinboelting; Christoph Heusser; Theodore S Jardetzky; Alexander Eggel
Journal:  Nat Commun       Date:  2020-01-08       Impact factor: 14.919

6.  IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.

Authors:  Be-Sheng Kuo; Chao-Hung Li; Jiun-Bo Chen; Yu-Yu Shiung; Chia-Yu Chu; Chih-Hung Lee; Yaw-Jen Liu; Je-Hung Kuo; Cindy Hsu; Hsiao-Wen Su; Ywan-Feng Li; Annie Lai; Yueh-Feng Ho; Yi-Ning Cheng; Hong-Xuan Huang; Meng-Chung Lung; Ming-Syue Wu; Fu-Hong Yang; Chen-Han Lin; William Tseng; Jasper Yang; Chia-Yin Lin; Pei-Hua Tsai; Heng-Kwei Chang; Yi-Jen Wang; Techeng Chen; Shugene Lynn; Mei-June Liao; Chang Yi Wang
Journal:  J Clin Invest       Date:  2022-08-01       Impact factor: 19.456

7.  High affinity targeting of CD23 inhibits IgE synthesis in human B cells.

Authors:  Marc Fellmann; Patrick Buschor; Silvan Röthlisberger; Fabian Zellweger; Monique Vogel
Journal:  Immun Inflamm Dis       Date:  2015-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.